{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:14:46Z","timestamp":1769516086357,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,6,17]],"date-time":"2017-06-17T00:00:00Z","timestamp":1497657600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470307"],"award-info":[{"award-number":["81470307"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Zhejiang Province (CN)","award":["LY13H080002"],"award-info":[{"award-number":["LY13H080002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00277-017-3021-y","type":"journal-article","created":{"date-parts":[[2017,6,17]],"date-time":"2017-06-17T03:07:38Z","timestamp":1497668858000},"page":"1353-1360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia"],"prefix":"10.1007","volume":"96","author":[{"given":"Yanmin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiasheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yamin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,17]]},"reference":[{"issue":"35","key":"3021_CR1","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27(35):6041\u20136051. doi:\n10.1200\/JCO.2009.25.0779","journal-title":"J Clin Oncol"},{"issue":"7","key":"3021_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/ajh.23180","volume":"87","author":"EJ Jabbour","year":"2012","unstructured":"Jabbour EJ, Kantarjian H, Eliasson L, Cornelison AM, Marin D (2012) Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol 87(7):687\u2013691. doi:\n10.1002\/ajh.23180","journal-title":"Am J Hematol"},{"issue":"4","key":"3021_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","volume":"32","author":"SB Dusetzina","year":"2014","unstructured":"Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL (2014) Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32(4):306\u2013311. doi:\n10.1200\/JCO.2013.52.9123","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"3021_CR4","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1179\/102453312X13336169155772","volume":"17","author":"S Jootar","year":"2012","unstructured":"Jootar S (2012) CML treatment in Asia-Pacific region. Hematology 17(Suppl 1):S72\u2013S74. doi:\n10.1179\/102453312X13336169155772","journal-title":"Hematology"},{"issue":"3","key":"3021_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.canep.2013.01.002","volume":"37","author":"AM Mendizabal","year":"2013","unstructured":"Mendizabal AM, Garcia-Gonzalez P, Levine PH (2013) Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries. Cancer Epidemiol 37(3):247\u2013254. doi:\n10.1016\/j.canep.2013.01.002","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"3021_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/bmt.2008.90","volume":"42","author":"GJ Ruiz-Arguelles","year":"2008","unstructured":"Ruiz-Arguelles GJ, Tarin-Arzaga LC, Gonzalez-Carrillo ML, Gutierrez-Riveroll KI, Rangel-Malo R, Gutierrez-Aguirre CH, Cantu-Rodriguez OG, Gomez-Almaguer D, Giralt S (2008) Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? Bone Marrow Transplant 42(1):23\u201328. doi:\n10.1038\/bmt.2008.90","journal-title":"Bone Marrow Transplant"},{"key":"3021_CR7","doi-asserted-by":"publisher","unstructured":"(2013) The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 121 (22):4439\u20134442. doi:\n10.1182\/blood-2013-03-490003","DOI":"10.1182\/blood-2013-03-490003"},{"issue":"6","key":"3021_CR8","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/leu.2008.401","volume":"23","author":"Y Luo","year":"2009","unstructured":"Luo Y, Lai XY, Tan YM, Shi JM, Zhao YM, Han XY, Zheng GF, Zhu XL, Sun J, Zheng YL, Wu GQ, He JS, Chen SY, Jin AY, Xie WZ, Ye XJ, Cai Z, Lin MF, Huang H (2009) Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase. Leukemia 23(6):1171\u20131174. doi:\n10.1038\/leu.2008.401","journal-title":"Leukemia"},{"issue":"17","key":"3021_CR9","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1182\/blood-2014-04-571570","volume":"124","author":"Y Luo","year":"2014","unstructured":"Luo Y, Xiao H, Lai X, Shi J, Tan Y, He J, Xie W, Zheng W, Zhu Y, Ye X, Yu X, Cai Z, Lin M, Huang H (2014) T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood 124(17):2735\u20132743. doi:\n10.1182\/blood-2014-04-571570","journal-title":"Blood"},{"issue":"12","key":"3021_CR10","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/leu.2013.159","volume":"27","author":"Q Jiang","year":"2013","unstructured":"Jiang Q, Xu LP, Liu DH, Liu KY, Gale RP, Zhang MJ, Jiang B, Zhang XH, Wang Y, Chen SS, Zhao XY, Chen H, Jiang H, Chen YH, Han W, Qin YZ, Liu YR, Lai YY, Lv M, Huang XJ (2013) Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia. Leukemia 27(12):2410\u20132413. doi:\n10.1038\/leu.2013.159","journal-title":"Leukemia"},{"issue":"4","key":"3021_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s12185-009-0292-7","volume":"89","author":"Y Zhao","year":"2009","unstructured":"Zhao Y, Liu L, Wang Y, Wu G, Lai X, Cao W, Luo Y, Tan Y, Shi J, Xie W, Ye X, Cai Z, Lin M, Huang H (2009) Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population. Int J Hematol 89(4):445\u2013451. doi:\n10.1007\/s12185-009-0292-7","journal-title":"Int J Hematol"},{"issue":"22","key":"3021_CR12","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, van Lierde MA, De Bock R, Verhoef G, Zach\u00e9e P, Berneman Z, Martiat P, Mineur P, Van Eygen K, MacDonald K, De Geest S, Albrecht T (2009 May 28) Abraham I (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113(22):5401\u20135411. doi:\n10.1182\/blood-2008-12-196543","journal-title":"Blood"},{"issue":"9","key":"3021_CR13","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1182\/blood-2004-09-3544","volume":"106","author":"C Crawley","year":"2005","unstructured":"Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M, Juliusson G, Nagler A, Gratwohl A, Passweg J, Komarnicki M, Vitek A, Mayer J, Zander A, Sierra J, Rambaldi A, Ringden O, Niederwieser D, Apperley JF (2005) Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 106(9):2969\u20132976. doi:\n10.1182\/blood-2004-09-3544","journal-title":"Blood"},{"issue":"8","key":"3021_CR14","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","volume":"112","author":"SJ Lee","year":"2008","unstructured":"Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RT (2008) Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 112(8):3500\u20133507. doi:\n10.1182\/blood-2008-02-141689","journal-title":"Blood"},{"issue":"10","key":"3021_CR15","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","volume":"115","author":"S Saussele","year":"2010","unstructured":"Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, Kolb HJ, Ho AD, Falge C, Holler E, Schlimok G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, Muller MC, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML study IV. Blood 115(10):1880\u20131885. doi:\n10.1182\/blood-2009-08-237115","journal-title":"Blood"},{"issue":"8","key":"3021_CR16","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.bbmt.2006.03.012","volume":"12","author":"A Grigg","year":"2006","unstructured":"Grigg A, Hughes T (2006) Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. Biol Blood Marrow Transplant 12(8):795\u2013807. doi:\n10.1016\/j.bbmt.2006.03.012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"3021_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.bmt.1703323","volume":"29","author":"D Gaziev","year":"2002","unstructured":"Gaziev D, Galimberti M, Polchi P, Angelucci E, Giardini C, Baronciani D, Andreani M, Persini B, Erer B, Sodani P, Manna M, Nicolini G, Visani G, Lucarelli G (2002) Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and\/or interferon at a single center: long-term results. Bone Marrow Transplant 29(1):1\u20138. doi:\n10.1038\/sj.bmt.1703323","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"3021_CR18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00277-011-1349-2","volume":"91","author":"P Topcuoglu","year":"2012","unstructured":"Topcuoglu P, Arat M, Ozcan M, Arslan O, Ilhan O, Beksac M, Gurman G (2012) Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients. Ann Hematol 91(4):577\u2013586. doi:\n10.1007\/s00277-011-1349-2","journal-title":"Ann Hematol"},{"issue":"3","key":"3021_CR19","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1182\/blood-2004-01-0027","volume":"105","author":"H Wang","year":"2005","unstructured":"Wang H, Cheng F, Cuenca A, Horna P, Zheng Z, Bhalla K, Sotomayor EM (2005) Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 105(3):1135\u20131143. doi:\n10.1182\/blood-2004-01-0027","journal-title":"Blood"},{"issue":"5","key":"3021_CR20","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/ajh.23691","volume":"89","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian H (2014) Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol 89(5):547\u2013556. doi:\n10.1002\/ajh.23691","journal-title":"Am J Hematol"},{"key":"3021_CR21","doi-asserted-by":"publisher","unstructured":"Hjorth-Hansen H, Stenke L, Soderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, Gjertsen BT, Hoglund M, Koskenvesa P, Lotfi K, Majeed W, Markevarn B, Ohm L, Olsson-Stromberg U, Remes K, Suominen M, Simonsson B, Porkka K, Mustjoki S, Richter J (2014) Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol. doi:\n10.1111\/ejh.12423","DOI":"10.1111\/ejh.12423"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-3021-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3021-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3021-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T22:27:33Z","timestamp":1498256853000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-3021-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,17]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["3021"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-3021-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,17]]}}}